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Abstract
In 2016, the third version of guidelines for the diagnosis and 
treatment of neuroendocrine tumors (NETs) has been pub-
lished by the European Neuroendocrine Tumor Society (EN-
ETS). These guidelines reflect the progress in treatment of 
NETs, and by comparing the newest guidelines with the first 
guidelines of 2001, this progress can be clearly recognized. 
Diagnostic accuracy has been increased by the introduction 
of PET-CT with Ga-labelled somatostatin analogs, and mul-
tiple new treatments and treatment schedules have been 
developed, like peptide receptor radiotherapy with radiola-
beled somatostatin analogs, or targeted therapies. Evidence 
and indications for these therapies are discussed in the EN-
ETS guidelines. In this review, we aim to show the progress 
in NET diagnosis and treatment on the basis of the advances 
in the guidelines, but also to discuss the unsolved questions 
and unmet needs which still remain.
© 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
In 2004, the European Neuroendocrine Tumor Society 
(ENETS) was founded by a group of European medical 
specialists in the field of neuroendocrine tumors (NETs). 
The main goal of the society since then has been “to inte-
grate basic and clinical research with teaching and to es-
tablish guidelines for the diagnosis and therapy for gas-
troenteropancreatic neuroendocrine tumors” [1]. The 
first guideline of this European consortium was a consen-
sus paper in 2001 on the imaging of NETs associated with 
the Multiple Endocrine Neoplasia type 1 (MEN-1) syn-
drome [2]. This paper was the result of a Delphi process 
initiated in 1998 by the European Network for Neuroen-
docrine Tumors, ENET. ENET was the basis on which 
ENETS was founded. The first set of guidelines by ENETS 
was published in 2004, and in 2016 the third version of 
these guidelines was published. In 2017, the second ver-
sion of the ENETS Standards of Care was published, 
thereby pursuing one of the main goals of the society. In 
this review, we will discuss the impact of these guidelines 
and standards on the clinical practice for patients with a 
NET over the recent years. 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Radiological and Nuclear Imaging
If a NET is suspected, the first guidelines of 2001 by 
ENET advocated a chest X-ray and abdominal ultraso-
nography as the imaging procedures of first choice [2]. In 
both functional and nonfunctional NET syndromes, so-
matostatin receptor-scintigraphy (SRS) was advised with 
a reported sensitivity and specificity at that time of 90 and 
80%, respectively. At this stage, only 111In-pentetreotide 
planar and SPECT images were available. Thereafter, CT 
and MRI were additionally performed for staging and for 
follow-up to document progression. SRS was already dis-
cussed to have limited use in localized insulinomas. If this 
was due to the small size of insulinomas or the expression 
profile of the somatostatin receptor subtypes was still un-
clear [3]. In case of a negative SRS, an enteroclysis was 
advised in patients with metastatic NETs from an un-
known primary source. At that time, 18FDG-PET/CT was 
considered not to be useful in the diagnostic workup. The 
guidelines written by ENET(S) in 2001 and 2004 advised 
to perform CT, or MRI in combination with SRS, without 
reporting on the limitations and evidence for these strat-
egies [2, 4]. For conventional imaging, the biggest im-
provement of the guidelines is that we can now substanti-
ate the diagnostic strategies based on evidence and that 
this has helped us also to identify the limitations and pit-
falls of the radiological and nuclear medicine modalities 
[5]. The sensitivity of CT is limited to 61–93% for detec-
tion of NETs, but its specificity is fairly high: reported to 
be between 71 and 100%. However, it seems that many 
small lesions can still be missed with the use of 3-phase 
CT. Compared to thin slice histopathology, CT only de-
tects 37.6% of liver metastases in patients undergoing a 
hemihepatectomy [6]. In these cases, superior imaging 
techniques could be used to exclude or identify patients 
for potential curative surgery. With the use of MRI, the 
detection rate of liver metastases already increased to 
48.8% in the same study. 
SRS was already fully incorporated in the first ENET(S) 
Standards and Guidelines. SRS has two specific advan-
tages: it often detects more metastases – at more sites – 
than conventional imaging, and it assesses the expres-
sion of somatostatin receptor subtypes on the tumor. 
The latter is required for peptide receptor radionuclide 
therapy (PRRT) using beta emitting somatostatin recep-
tor radioligands and for the selection of somatostatin 
analogs (SSAs) as first-line treatment. SRS detects tu-
mors that express the somatostatin receptor subtypes 2, 
3, and 5. These are mainly NETs, including pheochro-
mocytomas and other paragangliomas, but also menin-
giomas, medulloblastomas, and granulomatous diseases 
can display high expression of these somatostatin recep-
tor subtypes. The first SRS used [123I-Tyr3]octreotide, 
but a large number of drawbacks (short half-life, hepatic 
clearance resulting in high liver uptake and costs) made 
the development of alternative radiolabeled analogs nec-
essary [7]. SRS using 111In-pentetreotide (OctreoScan®) 
was the most widely used SRS until very recently [8–11]. 
Currently, SRS with 111In-pentetreotide is rapidly losing 
ground to PET/CT with gallium-labeled SSAs, because 
there are distinct advantages to this technique. Patients 
can be injected with the gallium-labeled SSA (68Ga-DO-
TA-TOC/TATE/NOC) only 1 h in advance of the scan-
ning procedure, whereas SRS can only be performed 
24 h after injection of 111In-pentetreotide. But the main 
advantage of 68Ga-SSA PET/CT is its higher detection 
rate as compared to SRS. Sensitivity and specificity of 
68Ga-SSA PET/CT for NET detection varies between 
88 and 95% in several studies and outperforms SRS in 
head-to-head comparisons [12–16]. For detection of 
bone metastases, 68Ga-SSA PET/CT even outperforms 
the current gold standard: the 99mTc-bisphosphonates 
scintigraphy [17, 18]. This makes 68Ga-SSA PET/CT the 
modality of choice for nuclear imaging in the current 
standards of care. The performance of the different gal-
lium-labeled SSAs (either DOTA-TOC, DOTA-TATE 
or DOTA-NOC) shows only small variations thus no 
specific preference exists [19, 20]. The most recent EN-
ETS guidelines already anticipate this change in diag-
nostic approach [5].
Also, several studies have now shown the usefulness of 
18F-FDG-PET/CT in the diagnostic workup of NETs. The 
sensitivity for detecting NETs is generally relatively low, 
ranging from 37–72%. Its usefulness, however, seems to 
be the better detection and prognostic stratification of 
higher grade NETs and neuroendocrine carcinomas 
(NECs). In tumors with high proliferation rates and sub-
sequent dedifferentiation, there can be loss of somatosta-
tin receptor expression with concomitant increase in glu-
cose metabolism and thus FDG avidity [21]. Further-
more, FDG avidity is a negative prognostic sign and might 
even be superior to the MIB-staining of the Ki67 protein 
for predicting prognosis [22]. With the upcoming WHO 
2017 guidelines for diagnosis and grading of NETs, the 
role of FDG-PET will be of most relevance for the diag-
nosis and therapeutic approach of patients with grade 3 
NETs and NECs. Also, the combination of 18F-FDG-
PET/CT and SRS imaging can be used to select patients 
for PRRT. Mainly high grade NETs, positive for FDG and 
SRS imaging, could benefit from PRRT [23].
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Thus, combining FDG and 68Ga-SSA PET/CT will give 
the most complete picture of NETs. It is superior in de-
tecting NETs, but the combination also gives a more com-
plete picture of the biological behavior of the NET by 
knowing the SRS and FDG avidity. 
Pathology Diagnosis
Selecting the optimal treatments and diagnostics for 
NET patients starts with making a correct diagnosis. 
This makes the Standards of Care on pathology reports 
of great value [24]. Uniform diagnosis is also required to 
be able to interpret results of trials and cohort studies. 
The groundwork for the standard for pathology report-
ing was finally published after a Delphi Consensus pro-
cess by Klimstra et al. [25] in 2010, and the diagnostic 
sequences for the pathological diagnosis of NETs are 
now well defined. It requires more than 50% of cells to 
stain positive for one of the neuroendocrine markers, 
synaptophysin or chromogranin. Tumors demonstrat-
ing lower percentages of cells with positive staining can 
be either designated as mixed adenoneuroendocrine 
carcinoma (MANEC) or a carcinoma with neuroendo-
crine differentiation. These should not be considered as, 
nor treated as a NET, and ENETS emphasized this fact 
by finally completely removing the goblet cell carcinoid 
(a misnomer) from the appendix NET guidelines [26]. 
ENETS produced its pathology grading system for fore-
gut and midgut NETs in 2007 [27, 28]. Two landmark 
papers were published explaining how this grading sys-
tem should work. Since then, several groups have pub-
lished on the clinical usefulness of such a system, and 
until now the cut-off criteria for the different tumor 
grades did not need to be changed [29–31]. Recently the 
cut-off for grading has been changed in the new WHO 
2017 guideline: a very slight change in the grade 1–2 cut-
off has been implemented (grade 1: Ki67 ≤3%) [32]. 
This small change will probably not influence clinical 
practice, but the newly advised classifying of grade 3 tu-
mors can possibly change future guidelines. The WHO 
2017 guideline advises to classify NETs with a Ki67 
>20% as either grade 3 NET (well-differentiated) or as 
grade 3 NEC (poorly differentiated) on the basis of mor-
phological characteristics as necrosis and differentia-
tion. Grade 3 NEC should hardly always be treated with 
systemic chemotherapy, whilst in well-differentiated 
grade 3 NET, there might still be room for PRRT or tar-
geted therapy. To aid in the grading of NETs immuno-
histochemical markers can be useful. Loss of Rb or ab-
normal p53 expression is often seen in grade 3 NEC, 
while loss of ATRX and DAXX expression is associated 
with well-differentiated NETs [33].
After the correct diagnosis of NET, staging should al-
ways be performed. ENETS has been leading the effort for 
a standardized approach. On behalf of ENETS, Rindi et 
al. [27, 28] published a TNM classification for NETs and 
this is also used in guidelines produced by ENETS and 
many other international studies and groups. A similar 
staging system was developed by the International Union 
for Cancer Control/American Joint Cancer Committee/
World Health Organization (UICC/AJCC/WHO), al-
though there are several differences identified between 
these two major systems. In a head to head comparison 
in a large cohort of pancreatic NETs, the ENETS system 
performed generally better [34]. In future guidelines, 
prognostic stratification through molecular markers may 
take a more prominent role [35].
Surgery
Early ENETS guidelines already defined preoperative 
standards and recognized the importance of a correct 
preoperative biochemical analysis. Especially patients 
with a small intestinal NET should be screened for sero-
tonin secretion by determining 5-hydroxyindoleacetic 
acid levels in the urine or plasma. Patients with elevated 
levels of this serotonin breakdown product might require 
SSA therapy to prevent carcinoid crises during surgery or 
other invasive procedures [36, 37]. ENETS recently up-
dated its recommendations in this field [38]. The only 
curative option for NETs has always been a surgical resec-
tion, and this has not changed until now and probably will 
remain for a long period of time [4, 39]. But while surgery 
can always be considered, current guidelines also define 
selected patients who might not need immediate treat-
ment and just have to be observed according to a well-
defined watchful waiting protocol. Observation seems 
reasonable in pancreatic NETs smaller than 2 cm; how-
ever, follow-up was only limited to 3 or 4 years in these 
studies [40, 41]. Importantly, these recommendations are 
based on studies in patients with inherited tumor syn-
dromes, like von Hippel Lindau disease, or MEN-1. As 
always, larger cohorts and preferably studies randomiz-
ing between observation or intervention would shed fur-
ther light on this issue. The generally slow growth rate of 
small pancreatic NETs will, however, require such a long 
follow-up and a large study cohort rendering further 
studies almost infeasible. Shared decision-making will 
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probably remain the standard for small nonfunctioning 
pancreatic NET in the coming years. However, ENETS 
has developed a plan to further study these issues in its 
ASPEN trial [42]. The second pancreatic or duodenal 
NET type that should not be primarily resected is the gas-
trinoma in MEN-1 patients. At presentation, these are of-
ten metastasized to lymph nodes requiring extensive re-
sections (like pancreaticoduodenectomy) [43, 44]. Cura-
tion rates are lower in MEN-1 patients, but prognosis is 
still better than in patients with sporadic gastrinomas 
[45]. Only in MEN-1 patients with multiple liver metas-
tases of gastrinomas is the survival significantly reduced 
[45, 46]. Therefore, in most MEN-1 patients with a gas-
trinoma smaller than 2 cm, only medical therapy with 
proton pump inhibitors (PPIs) is recommended and 
SSAs in patients with symptoms refractory to PPIs [47, 
48].
The extent of resection for appendiceal NETs also re-
mains a matter of debate. A large majority of appendiceal 
NETs are diagnosed incidentally during appendectomy, 
and most are often smaller than 1 cm. Appendectomy 
alone suffices for these patients as long-term survival is 
near 100% [26]. For appendiceal NETs larger than 2 cm, 
the risk of (lymph node) metastasis has been reported to 
be close to 25% with one study even finding lymph node 
metastases in 86% of these NET patients [49–51]. A right 
hemicolectomy is still recommended for these NETs, but 
in high-risk patients this procedure can result in morbid-
ity in up to 30% of patients [26, 52]. The survival benefit 
of this procedure has never been demonstrated. Hemico-
lectomy is still advised for appendiceal NETs >2 cm, but 
new and better evidence is urgently needed to select pa-
tients for this procedure.
For nonresectable or metastatic NETs, there has been 
a large increase in different therapeutic options. On the 
surgical side, there is further debate on whether resection 
of the primary tumor is indicated. Resection is currently 
recommended if curation can still be reached by resect-
ing the primary including all metastases or in symptom-
atic patients (e.g., with abdominal pain or diarrhea) [53]. 
Some studies also suggest a benefit for resection of the 
primary in asymptomatic, incurable patients increasing 
overall survival from 50 to 88 months in small bowel 
NET patients not undergoing resection to over 100 
months in patients undergoing resection [54]. These 
studies, however, are retrospective, and a large bias is 
very likely due to the selection of patients for surgery 
based on performance status and extent of mesenteric 
fibrosis. 
Systemic Therapy
Multiple medical therapies have become available for 
the treatment of metastatic NETs. All have shown their 
effect in randomized controlled trials, but head-to-head 
comparisons are not available. It is, therefore, difficult to 
select which drug is the most suitable for a selected pa-
tient. ENETS has developed an algorithm for treatment 
of metastatic NET aiding in the selection of the most suit-
able treatment for individual patients [55]. 
Somatostatin Analogs
The earliest ENETS guidelines could only recommend 
commencing SSAs in patients with functioning (hormone 
or peptide secreting) NETs since clinical evidence for their 
growth-inhibiting potential in nonfunctioning NETs was 
not available at that time. However, experimental studies 
as well as clinical experience in individual cases had al-
ready hinted at these effects [4, 56]. The recommendations 
were based on reduction of biomarkers and symptoms in 
patients with carcinoid syndrome, and only data on the 
initial responses were available (stable disease in 24–57% 
of patients). Nowadays, there is substantial clinical evi-
dence for the antiproliferative effect of SSAs. In the pre-
ENETS era, Scandinavian studies already showed growth 
inhibition in NETs with treatment of high doses of SSAs 
[57, 58]. First published was the PROMID trial, demon-
strating that 30 mg of octreotide LAR every 4 weeks in-
creased median progression-free survival (PFS) from 6.0 
months (placebo) to 14.3 months in patients with a meta-
static small intestinal NET [59]. This trial included also 
patients with not so severe carcinoid syndrome (36% of 
patients). The CLARINET trial followed several years lat-
er: including pancreatic and small intestinal NETs, me-
dian PFS increased from 18.0 months for placebo to me-
dian PFS not reached for lanreotide 120 mg every 4 weeks 
[60]. These results combined with the high tolerability fi-
nally led to ENETS advising first-line SSA treatment for 
patients with a pancreatic or small intestinal NET with a 
Ki67 tumor index of 10% or less [55]. Besides SSAs, EN-
ETS separately published instructions for safe use of sys-
temic therapy. [61]. Future interests lie in optimal dosing 
of SSAs, new forms of SSAs (single versus multiple SSA 
receptor), new formulations and whether to continue 
SSAs during second-line therapy, like PRRT using radio-
labeled SSAs and targeted therapy. 
Peptide Receptor Radionuclide Therapy
In the early ENETS guidelines, evidence for PRRT 
with radiolabeled SSAs was limited. The first large obser-
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vational study on PRRT using 177Lu-octreotate, including 
310 patients with gastroenteropancreatic NET was only 
published in 2008 by Kwekkeboom et al. [62]. A median 
PFS of 40 months was reported, which at that time was far 
superior to any other available therapy (chemotherapy or 
interferon-α). This was the basis for the recently pub-
lished NETTER-1 trial: patients with metastasized small 
intestinal NET were randomized to 177Lu-DOTA-octreo-
tate or octreotide LAR 60 mg per 4 weeks [63]. Median 
PFS was not reached in the PRRT arm at publication of 
the trial in 2017 after more than 2.5 years of follow-up, 
while median PFS in the octreotide LAR arm was 8.4 
months (hazard ratio: 0.21; 95% CI: 0.13–0.33; p < 0.001). 
Through this trial, 177Lu-DOTA-octreotate will probably 
be the first widely approved agent for PRRT. The ENETS 
Standard of Care for PRRT clearly describes evidence, 
treatment protocols, and patient selection for treatment 
with PRRT [64]. 
Targeted Therapy
The major advances in the field of targeted therapy for 
NETs can hardly be left unnoticed. Targeted therapy was 
first included in the ENETS guidelines of 2012 [65]. Cur-
rently, both sunitinib and everolimus are registered for 
the treatment of progressive metastatic pancreatic NET, 
and everolimus is also registered for progressive meta-
static small intestinal NET [55].
Everolimus was studied in at least 3 large randomized 
controlled trials. First published in 2011, the RADIANT-3 
trial studied patients with a progressive pancreatic NET, 
and in this trial everolimus increased PFS to 11.0 months 
compared to 4.6 months when treated with placebo (HR 
0.35, 95% CI: 0.27–0.45; p < 0.001) [66]. Shortly thereaf-
ter, the RADIANT-2 and RADIANT-4 trials were also 
published, studying PFS respectively in patients with car-
cinoid syndrome and nonfunctional NETs [67, 68]. 
Again, everolimus was shown to increase PFS with an HR 
for progression of, respectively, 0.77 (95% CI: 0.59–1.00, 
p = 0.026 one-sided) and 0.48 (95% CI: 0.35–0.67, p < 
0.001 one-sided), but toxicity is higher than treatment 
with SSAs [66–68].
Sunitinib has been studied in pancreatic NETs. In the 
SUNNET trial with 171 patients with a pancreatic NET, 
sunitinib increased PFS from 5.5 (placebo) to 11.4 months, 
resulting in a hazard ratio of 0.42 for progression (95% 
CI: 0.26–0.66, <0.001 two-sided) [69]. 
There is no specific preference for sunitinib or evero-
limus in progressive pancreatic NET as head-to-head 
comparisons are not available and, therefore, selection of 
therapy still is depending on the physician’s preferences 
and/or multidisciplinary team’s opinions [55]. For exam-
ple, for the patient with hypertension everolimus could be 
more suitable and vice versa for the patient with diabetes. 
The characteristics and treatment of side effects have 
been described in the standard of care for systemic ther-
apy [61]. An important role for ENETS will continue to 
be the judging of the available evidence for drugs to advise 
the clinician through its guidelines on selecting the most 
appropriate drug for the patient.
Interferon-Alpha
From the first guideline onwards, interferon-alpha has 
been recommended as second-line treatment after pro-
gression during treatment on SSAs [4, 55]. Interferon is a 
cytokine that has antiproliferative and antisecretory ef-
fect in NETs [70]. Our knowledge on the response to in-
terferon is largely based on the work of Öberg et al. [71–
73] in the 1990s. Partial response occurs in around 10–
15% of NETs, and this is comparable to treatment with 
SSAs. However, the burden of evidence for SSAs is higher, 
and the unfavorable side effects of interferon make SSAs 
the first-line treatment for metastatic NETs [74]. These 
side effects consist of flu-like symptoms and fatigue. 
While interferon is still recommended as second-line 
drug, newer therapies as PRRT and immunotherapy have 
less side effects, higher efficacy, and are supported by 
more evidence. A pegylated formulation, administered 
weekly, can decrease side effects [75]. The role of inter-
feron in future guidelines will probably be reduced to se-
lected patients with refractory carcinoid syndrome.
Chemotherapy
For the treatment of poorly differentiated grade 3 
NECs, chemotherapy is the first option. NECs are treated 
similar to small cell lung carcinomas, with platinum-
based chemotherapy, and this is stated in all ENETS 
guidelines [4, 76]. The combination of cisplatin with eto-
poside results in relatively high response rates of 17–67%, 
but median survival is still only 7–19 months [76–78]. 
Platinum-based chemotherapy has only little effect in 
NETs with Ki67 of 20–55%, and the use should be limited 
to poorly differentiated grade 3 NECs. New in current 
guidelines is the growing burden of evidence for second-
line treatments with oxaliplatin- or irinotecan-based re-
gimes [76, 77].
Since the first study of Moertel et al. [79] in 1980, the 
combination of streptozotocin and 5-fluorouracil (STZ/5-
FU) has been used for treatment of metastatic pancreatic 
NET. At that time, grading was not performed, and there-
fore STZ/5-FU could potentially be used in all metastatic 
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pancreatic NET. The 2016 ENETS guidelines limit the use 
of STZ/5-FU to NETs with a Ki67 of 5–20%, with bulky 
disease or rapid progression [55]. There is no evidence for 
chemotherapy in small intestinal NETs [80, 81]. Chemo-
therapy with temozolomide and capecitabine is currently 
not recommended by ENETS due to lack of evidence, but 
it shows promising results in phase II trials [55]. Combin-
ing chemotherapy with targeted inhibitors of angiogen-
esis (bevacizumab) looks promising, but has not proven 
superior to current regimes [82].
Interventional Radiology
Lastly, there have been major developments in the 
fields of interventional radiology for the treatment of 
NETs. Radiofrequency ablation is a commonly used 
technique for liver metastases smaller than 5 cm [83]. 
Larger tumors, especially in patients with liver-only dis-
ease, can be treated with embolization. Multiple options 
for embolization exist, namely bland embolization, che-
moembolization, or radioembolization. At this time, no 
preference can be made for a certain treatment due to 
lack of comparative trials, but especially bland emboliza-
tion and radioembolization with 90Ytrium show a very 
promising response rate of up to 80% in selected studies, 
but on average around 50% (complete and partial re-
sponse) [84–86]. Currently, no standard of care by EN-
ETS exists for embolization, but it is included in the cur-
rent guidelines for selected patients with high liver bur-
den.
Future Perspectives
When we compare the current with the past guide-
lines, it is clear that the field of NET research has come 
a long way in the past decades. It is impossible to mea-
sure the exact impact of these guidelines on patient care, 
but they do reflect the vast developments in the field. The 
first guidelines by ENET could only recommend a few 
diagnostic and treatment options with limited evidence 
to support the guidelines [2]. There has been a large in-
crease in diagnostic accuracy with the development of 
the 68Ga-SSA PET/CT, and the pathology reporting has 
been standardized to correctly diagnose patients and 
to select correct treatment. Multiple randomized con-
trolled trials have been published demonstrating the an-
tiproliferative effect of SSAs, targeted therapy and PRRT 
with radiolabeled SSAs. But the burden of evidence has 
also significantly increased: the first guideline was based 
on limited data and expert opinion mainly, but the most 
recent guidelines are based on prospective trials and are 
much more capable of quantifying benefits of diagnos-
tics and treatments. The most robust association, prov-
ing the effects of the guidelines is that with increasing 
treatment options in the guidelines, an increasing sur-
vival for NET patients has been recorded. ENETS of 
course does not develop new treatments, but the main 
role of ENETS should be to critically appraise the avail-
able evidence and therewith facilitate the transfer of 
knowledge to the clinicians and advise these clinicians 
on the correct treatment for their patients with the ex-
pertise of specialists behind the guidelines. With increas-
ing burden of evidence, an important next step for EN-
ETS is to develop the next guidelines with levels of evi-
dence and strength of recommendations [87]. Also, 
ENETS should highlight important clinical questions 
which are currently unanswered, resulting in unclear or 
unsupported recommendations. They are already doing 
so, and this has resulted in promising future research 
and trials. One of the main clinical enigmas remains the 
choice of second-line therapy when patients are progres-
sive while using SSA. PRRT with radiolabeled SSAs, tar-
geted therapy and several chemotherapy regimens have 
been proven effective in progressive patients. The results 
of the NETTER-1 trial are superior to any therapy pres-
ently available and will most probably become the sec-
ond-line therapy of choice. However, the sequence of 
therapy is arbitrary and based on the inclusion criteria 
for trials. The first true trial on sequencing therapy has 
recently been initiated in collaboration with ENETS: the 
SEQTOR trial compares the sequence of consecutively 
STZ/5-FU and everolimus [88]. 
But also in the surgical field, many questions remain. 
For which appendiceal NET is hemicolectomy indicated, 
and should we resect the primary tumor in metastatic 
small intestinal NET? But also, can surveillance be justi-
fied in small pancreatic NETs? ENETS have initiated pro-
spective trials studying resection of the primary and sur-
veillance of small pancreatic NET. 
Outside the guidelines, ENETS have developed their 
Centers of Excellence programs. The greatest benefit for 
patients is that expert centers are clearly identifiable, but 
also that patient care is monitored by the yearly submis-
sion of treatment data for quality control.
In conclusion, the guideline is only a small part in pa-
tient care. Reaching a high standard of patient care starts 
with organizing scientific meetings to exchange basic sci-
ence on which the eventual treatments of the future are 
based and ends with monitoring the quality of care at the 
bedside through the ENETS Centers of Excellence pro-
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gram. In between lie the guidelines which advise the cli-
nician on the treatment of choice. The effect of the EN-
ETS guidelines on patient care cannot simply be quanti-
fied, as end points would be biased and flawed, but 
sometimes evidence is not necessary to notice the benefit. 
For the ENETS guidelines, this benefit lies in its advice to 
the unexperienced clinician, the critical appraisal of the 
literature, and the identification of gaps in current evi-
dence.
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